The interactions of amphotericin B and itraconazole were studied in murine invasive candidiasis. Candida albicans -infected mice were treated for 10 consecutive days, 24 h after infection. Survival was monitored over 30 days and kidney cultures were done. Mice treated with amphotericin B (0.2 mg/kg/day intraperitoneally) or itraconazole (100 mg/kg/day by oral gavage in two divided doses/ day) had a 30-day survival of 20% or 40%. Concomitant administration of both drugs resulted in 100% mortality; 90% of mice treated with amphotericin B (1 mg/kg/day) survived. With the combination, 100% were dead by day 28 (P £ .001 vs. amphotericin B). With sequential therapy (i.e., 5 days with one drug and then 5 days with the other), survival was inferior to that with amphotericin B alone but similar to that with itraconazole alone. Kidney culture results confirmed the antagonism of the combination compared with amphotericin B alone. In treatment of murine invasive candidiasis, the concomitant or sequential use of amphotericin B and itraconazole results in a negative interaction.
While theory predicts that azole antifungal drugs will antagoother animal models (e.g., cryptococcosis, trichosporonosis, and candidiasis), positive effects are noted [6, 14, 15] . Thus, nize the effects of amphotericin B in the treatment of fungal infections, it has been difficult to prove this [1] . For example, both drug-specific and fungus-specific factors may dictate the type of interaction seen with combined use of polyene and in vitro testing frequently predicts drug antagonism [2 -4] , yet experience with in vivo models of mycoses often show additive azole antifungal drugs. Despite these concerns regarding antagonistic interactions or synergistic effects [5 -8] . Moreover, the effects of an azole on the efficacy of amphotericin B seem to be specific to the between some azoles with amphotericin B, the use of azoles concomitantly with amphotericin B or sequentially, after an azole, and broad generalizations may not accurately reflect the interaction [1, 9, 10] .
initial course of amphotericin B, is commonly observed in clinical practice. Therefore, we conducted this study using a A theory to explain these drug-to-drug differences has been advanced [11] . Briefly, lipophilic azoles, such as itraconazole, well-described murine model of invasive candidiasis to evaluate potential interactions between amphotericin B and itraconaare thought to block the interaction of amphotericin B at the cell membrane, the major site of action of amphotericin B, by zole in the treatment of invasive candidiasis in this mouse model. adsorbing to the cell membrane surface. Water-soluble azoles, such as fluconazole, on the other hand, partition into the fungal cell and do not accumulate on the cell membrane, thereby Materials and Methods allowing amphotericin B to bind to cell membrane ergosterol. Thus, the interaction is more complicated than merely inhibiFungi. Candida albicans 64, a well-characterized isolate in tion of ergosterol synthesis by the azole resulting in a decrease our laboratory [5, 10] , was maintained in stock culture at 070ЊC.
in the major amphotericin B target in the fungal cell membrane.
When needed for an experiment, blastoconidia were grown for 48
In addition to these drug-specific concerns, there may be h on fresh Sabouraud dextrose agar slants. Blastoconidia were differences in the end result of such combination therapy deharvested and washed twice with sterile saline, and desired concenpending on the fungus involved. For example, several different trations were prepared in saline.
animal models of aspergillosis have been used to demonstrate
Mice. Three-week-old male ICR mice (weight, 16-20 g) were obtained from Harlan Sprague-Dawley (Indianapolis). Mice were antagonism of amphotericin B with azoles [7, 12, 13 ], yet in acclimatized for at least 2 days before infection. They were fed food and water ad libitum.
Compounds. Amphotericin B with sodium deoxycholate was purchased from Sigma (St. Louis) and was stored as a stock solu-additional 4 mice/group were included. Treatment was begun 24 h after infection and continued for 10 days. Itraconazole was given by oral gavage twice daily and amphotericin B was given by intraperitoneal injection once daily. The polyethylene glycol vehicle for itraconazole was well-tolerated in this and our previous experiments, and no clinically evident toxicity was observed. In selected experiments, 1 day after completion of therapy or on day 30, 2 mice in each group were sacrificed for culture of kidney. Organs were homogenized (Tissumizer; Tekmar, Cincinnati), and serial dilutions were plated on blood agar plates and incubated for 48 h, and then colonies were counted.
Itraconazole serum concentrations. One mouse was selected at random, and blood was sampled 4 h after it received itraconazole on days 2, 4, 6, 8, and 10. On day 12, an additional mouse had blood taken 24 h after the last dose of itraconazole. Serum concentrations were measured by bioassay using Candida kefyr as the indicator organism by an adaptation of the method used at the Fungus Testing Laboratory, San Antonio, Texas.
Statistical analysis. Survival was plotted as Kaplan-Meier curves, and groups were compared by log rank analysis. Comparisons of colony-forming units from kidney cultures were analyzed by t test using a commercially available statistical program (SPSS, Chicago). Significance was defined as P õ .05. 21, with a median survival time (MST) of 5 days. Itraconazole afforded significantly improved survival compared with that in or itraconazole survived to day 30, with MSTs of 18 and 29 controls (P Å .002), but amphotericin B alone or in combinadays, respectively. No enhanced activity of the combination tion with itraconazole did not (P ú .05). Survival of all groups compared with either drug used alone was seen. at 30 days was õ50%. The combination of amphotericin B A second experiment focused on the effects of such combinaand itraconazole was associated with 100% mortality by day tion therapy when optimal doses of amphotericin B were used. 23, with an MST of 17 days (P Å .011 compared with itraconaIn this experiment, amphotericin B at 1 mg/kg/day with or zole alone; P ú .05 compared with amphotericin B alone). In without itraconazole at 100 mg/kg/day was studied. As shown contrast, 20% and 40% of mice treated with amphotericin B in figure 2A, all control mice had died by day 15, with an MST of 8 days. Eighty percent of mice treated with itraconazole alone also died by day 30, with an MST of 21 days (P Å .008 compared with control). In mice treated with amphotericin B, survival to day 30 was 90%, with MSTs of ú30 days. As in the first experiment, mice treated with both drugs together for 10 days had poor survival, with 100% dead by day 28 and an MST of 10 days (P £ .001 compared with amphotericin B alone; P Å .053 compared with itraconazole alone). In addition to the higher dose of amphotericin B used in this experiment, the same low doses of amphotericin B were also used in this experiment, and the results were identical to those presented in the first experiment (data not shown).
Results

Concomitant therapy with amphotericin B and itraconazole.
Kidney cultures obtained 1 day after the end of therapy showed an Ç2-log decrease in colony-forming units in ampho-/ 9d46$$ju27 04-02-98 11:05:11 jinfa UC: J Infect tericin B -treated mice compared with control mice (P õ .05 of amphotericin B and itraconazole resulted in a decrease in the efficacy seen with amphotericin B when used as a single vs. all groups; figure 2B ). In contrast, no decrease was seen in mice that received itraconazole alone or the combination.
agent for the entire course of therapy. Kidney cultures were done on day 30 in mice surviving to Sequential use of amphotericin B and itraconazole. To investigate whether sequential administration of the two antifunthat point (figure 3B). Amphotericin B alone resulted in a significant decrease in colony-forming units compared with gal drugs had any interactions, mice were infected as in the previously described experiments and treated with a combinaitraconazole and amphotericin B, followed by itraconazole (P õ .05). There were no surviving mice in the other groups, so tion of amphotericin B and itraconazole or with 5 days of one of the drugs followed by 5 days of the other drug for a total these cultures could not be done. Itraconazole serum concentrations were determined for 2 of 10 days of therapy. As shown in figure 3A , control mice all died by day 16, with an MST of 13 days. In contrast, 90% of mice each on days 2, 4, 6, 8, and 10, 4 h after the dose was given, and on day 12, 24 h after the last dose of itraconazole. amphotericin B -treated mice survived until the end of the experiment on day 30. Similar to the earlier experiments, amSerum concentrations were detectable by day 4 (0.3 mg/mL), increasing to 0.8 mg/mL at day 6 and 2.8 mg/mL at day 8, photericin B plus itraconazole (survival, 0; MST, 14 days) was less effective than amphotericin B alone (survival, 90%; P £ then decreasing slightly to 2.0 mg/mL at day 10; itraconazole remained detectable 24 h after the last dose of therapy (day .001) and similar in efficacy to itraconazole alone (survival, 10%; MST, 13 days; P ú .05). Initial treatment with amphoteri-12, 1.0 mg/mL). Steady state appeared to be reached by day 8. cin B for 5 days followed by itraconazole for 5 days resulted in a delay in mortality, but after about 2 weeks into the experiDiscussion ment, the slope of the mortality was similar to that seen in mice treated with itraconazole alone. At 30 days, 30% of mice
The data presented herein demonstrate a remarkable negative interaction when amphotericin B is combined concomitantly treated with amphotericin B followed by itraconazole survived, with an MST of 21 days. When mice were treated with itraconaor sequentially with itraconazole. These results are in striking contrast with those obtained in an earlier study of amphotericin zole first and then with amphotericin B, all mice died by day 27 and the MST was 18 days. Thus, all possible combinations B and fluconazole in the same murine model of invasive candidiasis, in which the combination of drugs provided enhanced activity [5] . This apparent antagonism of the effects of amphotericin B by itraconazole was demonstrable by measuring survival over a 30-day period, MST, and cultures of the major target organ in this model, the kidney. Thus, it is clear from this work and that of others that the outcome of combination polyene-azole therapy depends on the identity of the azole. These data extend observations obtained from different animal models of aspergillosis [7, 12, 13] and indicate that an antagonistic interaction between amphotericin B and itraconazole is now demonstrable in vivo in two different mycoses. Clearly, given the potential for using these two drugs in combination either concomitantly or in sequence in clinical medicine, there is a need to study this form of therapy in animal models of cryptococcosis, histoplasmosis, and coccidioidomycosis, as well as in other mycoses. Until the mechanisms underlying these drug interactions are better understood, there is little else to rely on when making therapeutic decisions for the treatment of fungal diseases.
As discussed by Scheven and colleagues [11, 16, 17] , one mechanism for the antagonism of amphotericin B and itraconazole may be that the lipophilic itraconazole blocks the interaction of amphotericin B binding to the fungal cell membrane. This would explain differences seen with itraconazole and flu- 
